BRPI1015338B8 - formulação farmacêutica líquida, uso de um sal, composto e recipiente equipado com um agregado de gotejamento - Google Patents

formulação farmacêutica líquida, uso de um sal, composto e recipiente equipado com um agregado de gotejamento

Info

Publication number
BRPI1015338B8
BRPI1015338B8 BRPI1015338A BRPI1015338A BRPI1015338B8 BR PI1015338 B8 BRPI1015338 B8 BR PI1015338B8 BR PI1015338 A BRPI1015338 A BR PI1015338A BR PI1015338 A BRPI1015338 A BR PI1015338A BR PI1015338 B8 BRPI1015338 B8 BR PI1015338B8
Authority
BR
Brazil
Prior art keywords
salt
compound
drip
aggregate
pharmaceutical formulation
Prior art date
Application number
BRPI1015338A
Other languages
English (en)
Inventor
Lopez De Diego Heidi
Treppendahl Svend
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42669509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1015338(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of BRPI1015338A2 publication Critical patent/BRPI1015338A2/pt
Publication of BRPI1015338B1 publication Critical patent/BRPI1015338B1/pt
Publication of BRPI1015338B8 publication Critical patent/BRPI1015338B8/pt
Publication of BRPI1015338C1 publication Critical patent/BRPI1015338C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)

Abstract

formulação farmacêutica líquida, método para o tratamento de uma doença, uso de um sal, sal de um composto, composto, recipiente equipado com um agregado de gotejamento proporciona-se formulações líquidas de sais de adição de ácido láctico de 1-[2,4-dimetilfenilsulfanil)-fenil]piperazina.
BRPI1015338A 2009-04-24 2010-04-16 formulação farmacêutica líquida, uso de um sal, composto e recipiente equipado com um agregado de gotejamento BRPI1015338C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200900531 2009-04-24
DKPA200900531 2009-04-24
PCT/DK2010/050084 WO2010121621A1 (en) 2009-04-24 2010-04-16 Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Publications (4)

Publication Number Publication Date
BRPI1015338A2 BRPI1015338A2 (pt) 2016-05-31
BRPI1015338B1 BRPI1015338B1 (pt) 2021-01-05
BRPI1015338B8 true BRPI1015338B8 (pt) 2021-05-25
BRPI1015338C1 BRPI1015338C1 (pt) 2021-08-10

Family

ID=42669509

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015338A BRPI1015338C1 (pt) 2009-04-24 2010-04-16 formulação farmacêutica líquida, uso de um sal, composto e recipiente equipado com um agregado de gotejamento

Country Status (35)

Country Link
US (4) US8940746B2 (pt)
EP (1) EP2421534B1 (pt)
JP (1) JP5722879B2 (pt)
KR (1) KR101779214B1 (pt)
CN (2) CN104693145A (pt)
AR (2) AR076400A1 (pt)
AU (1) AU2010238946B2 (pt)
BR (1) BRPI1015338C1 (pt)
CA (1) CA2759456C (pt)
CL (1) CL2011002631A1 (pt)
CO (1) CO6450649A2 (pt)
CR (1) CR20110554A (pt)
DK (1) DK2421534T3 (pt)
DO (2) DOP2011000319A (pt)
EA (1) EA021122B1 (pt)
ES (1) ES2512719T3 (pt)
GE (1) GEP20135938B (pt)
HK (1) HK1206732A1 (pt)
HR (1) HRP20140880T1 (pt)
IL (1) IL215362A0 (pt)
MA (1) MA33298B1 (pt)
MX (1) MX2011011119A (pt)
MY (1) MY155288A (pt)
NZ (1) NZ596431A (pt)
PL (1) PL2421534T3 (pt)
PT (1) PT2421534E (pt)
RS (1) RS53539B1 (pt)
SG (1) SG175124A1 (pt)
SI (1) SI2421534T1 (pt)
SM (1) SMT201400159B (pt)
TN (1) TN2011000504A1 (pt)
TW (1) TWI461224B (pt)
UA (1) UA106985C2 (pt)
WO (1) WO2010121621A1 (pt)
ZA (1) ZA201107731B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20135938B (en) 2009-04-24 2013-10-10 H Lundbeck As Liquid pharmaceutical formulations of 1-[2-(2,4-dimethylsulfanyl)phenyl]piperazine
BR112015006075B1 (pt) 2012-09-19 2022-10-04 Sandoz Ag Composto cristalino, composição farmacêutica, uso do composto cristalino, hidrato cristalino do bromidrato de vortioxetina, método para a preparação do hidrato cristalino de bromidrato de vortioxetina, método para a preparação do composto cristalino e uso do hidrato cristalino de bromidrato de vortioxetina
AU2014286308B2 (en) 2013-07-01 2018-05-10 Lek Pharmaceuticals D.D. 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form
US9822086B2 (en) 2014-01-31 2017-11-21 Egis Gyogyszergyar Zrt. Process for the preparation of vortioxetine salts
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
GB201419261D0 (en) 2014-10-29 2014-12-10 Therakind Ltd Formulations
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
JO3456B1 (ar) * 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
US10562872B2 (en) 2016-02-08 2020-02-18 H. Lundbeck A/S Synthesis of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
CN109310691A (zh) 2016-07-01 2019-02-05 H.隆德贝克有限公司 用于快速开始抗抑郁作用的给药方案
CN106518807A (zh) * 2016-09-17 2017-03-22 北京万全德众医药生物技术有限公司 乳酸沃替西汀晶型的制备方法
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN107011289A (zh) * 2017-03-10 2017-08-04 万全万特制药（厦门）有限公司 沃替西汀β晶型的制备方法
GB2564887A (en) * 2017-07-26 2019-01-30 Azad Pharmaceutical Ingredients Ag New route of synthesis to vortioxetine salts
JP2023520016A (ja) 2020-04-03 2023-05-15 ハー・ルンドベック・アクチエゼルスカベット 感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
DE602004016316D1 (de) 2003-04-04 2008-10-16 Lundbeck & Co As H 4-(2-phenylsulfanyl-phenyl)-piperidin-derivate als serotonin-wiederaufnahme-hemmer
ES2379200T5 (es) * 2006-06-16 2021-10-20 H Lundbeck As Bromhidrato de 1-[2-(2,4-Dimetilfenilsulfanil)fenil]piperazina como compuesto con recaptación de serotonina combinada con actividad 5-HT3 y 5-HT1A para el tratamiento del deterioro cognitivo
EP2044020B1 (en) 2006-06-16 2011-05-04 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TWI405588B (zh) * 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
GEP20135938B (en) 2009-04-24 2013-10-10 H Lundbeck As Liquid pharmaceutical formulations of 1-[2-(2,4-dimethylsulfanyl)phenyl]piperazine

Also Published As

Publication number Publication date
UA106985C2 (uk) 2014-11-10
RS53539B1 (en) 2015-02-27
HK1206732A1 (en) 2016-01-15
CA2759456C (en) 2017-10-31
US20170224677A1 (en) 2017-08-10
SG175124A1 (en) 2011-12-29
CR20110554A (es) 2012-02-14
EP2421534B1 (en) 2014-09-03
BRPI1015338C1 (pt) 2021-08-10
AU2010238946B2 (en) 2013-03-28
EA021122B1 (ru) 2015-04-30
MY155288A (en) 2015-09-30
MX2011011119A (es) 2011-11-04
KR101779214B1 (ko) 2017-09-18
TWI461224B (zh) 2014-11-21
IL215362A0 (en) 2011-12-29
KR20120022809A (ko) 2012-03-12
AR122051A2 (es) 2022-08-10
US10857149B2 (en) 2020-12-08
SI2421534T1 (sl) 2014-11-28
CN104693145A (zh) 2015-06-10
BRPI1015338B1 (pt) 2021-01-05
DOP2011000319A (es) 2012-02-29
ZA201107731B (en) 2013-02-27
DOP2012000211A (es) 2013-03-31
CA2759456A1 (en) 2010-10-28
NZ596431A (en) 2012-12-21
PT2421534E (pt) 2014-10-29
EA201171287A1 (ru) 2012-04-30
JP5722879B2 (ja) 2015-05-27
MA33298B1 (fr) 2012-05-02
SMT201400159B (it) 2015-01-15
EP2421534A1 (en) 2012-02-29
US8940746B2 (en) 2015-01-27
DK2421534T3 (da) 2014-10-13
US10034876B2 (en) 2018-07-31
CL2011002631A1 (es) 2012-04-09
CN102405048A (zh) 2012-04-04
TN2011000504A1 (en) 2013-05-24
GEP20135938B (en) 2013-10-10
PL2421534T3 (pl) 2014-12-31
HRP20140880T1 (hr) 2014-11-07
TW201041604A (en) 2010-12-01
US20150094316A1 (en) 2015-04-02
ES2512719T3 (es) 2014-10-24
US20120035188A1 (en) 2012-02-09
US20190167667A1 (en) 2019-06-06
US9475748B2 (en) 2016-10-25
WO2010121621A1 (en) 2010-10-28
JP2012524735A (ja) 2012-10-18
AU2010238946A1 (en) 2011-12-08
CO6450649A2 (es) 2012-05-31
AR076400A1 (es) 2011-06-08
BRPI1015338A2 (pt) 2016-05-31

Similar Documents

Publication Publication Date Title
BRPI1015338C1 (pt) formulação farmacêutica líquida, uso de um sal, composto e recipiente equipado com um agregado de gotejamento
PE20150998A1 (es) Inhibidores de histona demetilasas
MX2011012344A (es) Sales de disacarina, acido difumarico, acido di-1-hidroxi-2-naftoi co y acido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino) butilo.
BRPI1013237A2 (pt) formulação aquosa estável, estéril, forma de dosagem unitária farmacêutica, recipiente vedado, kit, métodos para tratar um distúrbio ou doença de células b em um humano, para esgotar células b que expressam cd-19 em um paciente humano, e para intensificar a estabilidade de armazenamento de uma formulação aquosa, e, processo para preparar uma formulação
CR11119A (es) Derivados de indazol oxadiazol sustituidos para uso como agonistas esfingozina 1-fosfato (sip)
CL2012003009A1 (es) Acido3-(((3-butil-3-etil-(metiloxi)-1-1-dioxido-5-fenil-2,3,4,5-tetrahidro-1,4benxotiazepin-8-il)-metil)-amino)-pentanodioco; composicion farmaceutica que lo comprende; y su uso en un tastorno metabolico. pct.
EA201071409A1 (ru) Новые соли (4-{[(5-{[(3-хлорфенил)метил]окси}-2-метилфенил)карбонил]амино}-3-метилфенил)уксусной кислоты
ES2560676T3 (es) Combinación farmacéutica para el tratamiento del dolor
BRPI0820471A2 (pt) Derivados de 1,2,3-triazol para uso como inibidores de estearoil-coa dessaturase
BRPI0820438A2 (pt) Composição radiofarmacêutica estabilizada, método para a preparação da mesma, e, uso de ácido gentísico ou um sal do mesmo com um cátion biocompatível.
ECSP11011095A (es) Amidas del ácido 4-(1,2,3,4-tetrahidroisoquinolina-2-il)-4-oxobutírico sustituidas como moduladores de KCNQ2/3.
NI200900161A (es) Sales de adición de ácido, hidratos y polimorfos de la etil - amida del ácido 5 - (2,4 -dihidroxi -5- isopropil - fenil) -4- (4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas.
CL2013002996A1 (es) Uso de aclidinio o sus sales o cualquiera de sus estereoisomeros o mezcla de estereoisomeros, o una sal farmeceuticamente aceptable o solvato del mismo para la preparacion de un medicemnto util en mejorar la calidad del sueño en enfermos respiratorios.
BR112014009165A2 (pt) sal e uso médico
BR112012020377A2 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
CL2008000797A1 (es) Composicion farmaceutica liquida que comprende una sal de 4-(2-(4-metilfenilsulfanil)fenil)piperidina seleccionada entre la sal de adicion de acido dl-lactico, glutarico, l-aspartico y glutamico; uso de dicha composicion para tratar trastornos del es
CL2013000085A1 (es) Sal cristalina de (s)-3-[(s)-1-(4-clorofenoxi)-2-metilpropil]pirrolidina y acido clorhidrico en una relacion molar 1:1; composicion farmaceutica; proceso de preparacion; y su uso para el tratamiento del dolor, un trastorno depresivo, un trastorno afectivo, obesidad, entre otras.
BR112012000410A2 (pt) uso de benzidamina ou dos sais de adição de ácido, método para o tratamento de uma doença, e, composição farmacêutica
GB201004677D0 (en) New salt
EP2307015A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS BASED ON DERIVATIVES OF BENZAMIDINE OR SALTS THEREOF, AND ALENDRONIC ACID OR SALTS THEREOF
BR112015005489A2 (pt) composição farmacêutica para administração oral com dissolução e/ou absorção aperfeiçoadas
CY1115793T1 (el) Υγρα σκευασματα αλατων 1-[2-(2,4-διμεθυλοφαινυλοσουλφανυλο)φαινυλο]πιπεραζινης
CL2012001170A1 (es) Procedimiento para preparar una forma cristalina de la sal de colina del ácido [4,6-bis(dimetilamino)-2-(4-{[4-(trifluorometil)benzoil]amino}bencil)pirimidin-5-il]acetico; sal de colina cristalina del compuesto; composición farmacéutica que la comprende; y uso de una enfermedad asociada con la actividad de crth2.
CU20090151A7 (es) Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas
TH133984B (th) เกลือไดแซคคาริน, กรดไดฟูมาริก, กรดได-1-ไฮดรอกซี-2-แนพโทอิกหรือกรดโมโน- เบนโซอิกของ 4-(ไดเมทิลอะมิโน)บิวทิล 2-(4-((2-อะมิโน-4-เมทิล-6-(เพนทิลอะมิโน) ไพริมิดิน-5-อิล)เมทิล)ฟีนิล)อะซิเตท

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/04/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2609 DE 05/01/2021 QUANTO A QUALIFICACAO DO TITULAR.